Health Insurance (Section 3C - Lutetium PSMA Treatment) Determination 2025
I, Mary Warner, delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 30 April 2025
Mary Warner
Assistant Secretary
Diagnostic Imaging and Pathology Branch
Medicare Benefits and Digital Health Division
Health Resourcing Group
Department of Health and Aged Care
1 Name...................................................1
2 Commencement............................................1
3 Authority................................................1
4 Definitions...............................................1
5 Treatment of relevant services....................................2
6 Application of provisions of the General Medical Services Table................3
7 Application of provisions of the Diagnostic Imaging Services Table..............3
8 Limitation of item 61528.......................................3
9 Schedules................................................3
Schedule 1 – General medical services 4
Schedule 2 – Diagnostic imaging services 5
This instrument is the Health Insurance (Section 3C – Lutetium PSMA Treatment) Determination 2025.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 July 2025. | 1 July 2025 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.
Act means the Health Insurance Act 1973.
disease progression means either or both:
PET means positron emission tomography.
PSA means prostate-specific antigen
PSMA means prostate specific membrane antigen
nuclear medicine credentialled specialist means a specialist or consultant physician whose name is included in a register, given to the Chief Executive Medicare by the JNMCAC, of participants in the Joint Nuclear Medicine Specialist Credentialling Program of the JNMCAC.
relevant provisions means all provisions, of the Act and regulations made under the Act, and the National Health Act 1953 and regulations made under the National Health Act 1953, relating to medical services, professional services or items.
relevant service means a health service, as defined in subsection 3C(8) of the Act, that is specified in a Schedule.
report means a report prepared by a medical practitioner.
(R) has the meaning given by clause 1.2.15 of the diagnostic imaging services table.
Schedule means a Schedule to this instrument.
SPECT means single-photon emission computed tomography.
SUV means standardised uptake value.
Note: The following terms are defined in subsection 3(1) of the Act:
For subsection 3C(1) of the Act, a relevant service, provided in accordance with this instrument and as a clinically relevant service, is to be treated, for the relevant provisions, as if:
Clause 5.4.1 shall have effect as if Items 16050 and 16055 of Schedule 1 of this Determination were also specified in clause 5.4.1 of the General Medical Services Table.
Clause 2.4.6 shall have effect as if Item 61528 of Schedule 2 of this Determination was also specified in subclause 2.4.6 of the Diagnostic Imaging Services Table.
Item 61528 does not apply unless:
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Category 3 – Therapeutic Procedures | ||
GroupT3 -Therapeutic Nuclear Medicine | ||
Column 1 Item | Column 2 Description | Column 3 Fee ($) |
Administration of Lutetium 177 PSMA, followed within 36 hours by whole body Lu-PSMA SPECT, for treatment of a patient with metastatic castrate resistant prostate cancer who is:
Applicable once per cycle, up to a maximum of 2 cycles in the initial treatment phase. | 8,000.00 | |
16055 | Administration of Lutetium 177 PSMA, followed within 36 hours by whole body Lu-PSMA SPECT, for treatment of a patient with metastatic castrate resistant prostate cancer, if:
Applicable once per cycle, up to a maximum of 4 cycles in the continuing treatment phase. | 8,000.00 |
Category 5 – Diagnostic Imaging Services | ||
Group I4 – Nuclear Medicine Imaging | ||
Subgroup 2 – PET | ||
Column 1 Item | Column 2 Description | Column 3 Fee ($) |
61528 | Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.
(R) (Anaes.)
| 1,300.00 |